Oxidative-stress resilience
Cell studies report lower reactive-oxygen accumulation and less necrotic death under experimental stress.
Explore the research →EDR TRIPEPTIDE & NEURAL-AGEING RESEARCH
Pinealon
An experimental peptide explored for cognition, brain health and age-related neurological change. Current evidence is mainly preclinical.
Oxidative stressLearning and memoryGene regulation
A defined sequence with an almost entirely preclinical evidence basePinealon has peer-reviewed cell and animal studies, but no modern controlled human treatment programme has established cognitive benefit, dose, route, pharmacokinetics or long-term safety.
FOLLOW THE FULL PICTUREFrom interest to evidence, quality and the numbers.
What makes Pinealon scientifically interesting?
Pinealon is mainly discussed around brain health, memory and healthy ageing. Experimental research looks at how nerve cells respond to stress and damage, which is why the peptide has become interesting to people thinking about cognitive resilience and maintaining brain function with age.
Learning and memory models
Rat studies have examined cognition after prenatal hyperhomocysteinaemia, hypoxia, hypothermia and diabetes.
Explore the research →Gene-expression hypothesis
Research explores whether EDR can interact with DNA-associated processes and alter selected neuronal gene expression.
Explore the research →Brain-ageing interest
The peptide is discussed as a short bioregulator for age-related cognitive resilience.
Explore the research →THE SCIENCE BIT
A small peptide exploring how neural cells handle stress.
Pinealon is the three-amino-acid sequence glutamate–aspartate–arginine. Experiments examine oxidative stress, cell survival and gene-expression-related effects in neural research.
Its small size does not by itself establish brain delivery or a therapeutic effect. A specific, validated receptor mechanism and controlled human efficacy remain open questions.
See the studies & trials →- EDR sequence
- Three amino acids
- Oxidative stress
- Experimental cell responses
- Gene expression
- A developing hypothesis
How this connects to the research
Predominantly laboratory and animal evidence.
Read a primary source ↗FROM MOLECULE TO TISSUE
Where Pinealon connects with the body
These are the tissues and biological systems behind the interest in Pinealon.
- Neural cells
- Stress-resilience experiments.
- Cell nucleus
- Gene-regulation research.
- Brain models
- Learning and ageing studies.
The research behind the interest
Oxidative-stress resilience
Cell studies report lower reactive-oxygen accumulation and less necrotic death under experimental stress.
These findings come from cell systems and do not establish neuroprotection in a person.
Cellular evidenceExplore the studies →Learning and memory models
Rat studies have examined cognition after prenatal hyperhomocysteinaemia, hypoxia, hypothermia and diabetes.
Positive behavioural signals are useful for hypothesis-building but remain several translation steps from human cognitive benefit.
Animal evidenceExplore the studies →Gene-expression hypothesis
Research explores whether EDR can interact with DNA-associated processes and alter selected neuronal gene expression.
Molecular effects have not been connected to a validated clinical endpoint or human dose-response.
Mechanistic evidenceExplore the studies →Brain-ageing interest
The peptide is discussed as a short bioregulator for age-related cognitive resilience.
The ageing narrative relies on preclinical and regional literature rather than modern controlled human outcomes.
Predominantly preclinical evidenceExplore the studies →Studies & trials
Studies & trials
Original publication · PubMed · trial registry where availablePinealon increases cell viability under oxidative stress ↗
Cerebellar granule cells, neutrophils and PC12 cells
Pinealon produced dose-dependent restriction of reactive-oxygen accumulation and reduced necrotic cell death in experimental systems.
The study also reported altered ERK1/2 activation and cell-cycle effects; it did not test cognition or safety in people.
Pinealon in rat offspring exposed to prenatal hyperhomocysteinaemia ↗
Rat offspring in a prenatal methionine-loading model
The study reported improved cognitive performance and changes in cerebellar cell-death markers after Pinealon.
This specialised developmental model cannot establish benefit for adult human memory or ageing.
Pinealon and Cortexin in aged rats exposed to hypoxia or hypothermia ↗
18-month-old rats in two stress models
The report examined behaviour and neurochemical processes after treatment in acute hypoxia and mild hypothermia models.
It does not supply a human treatment effect, route conversion or maintenance protocol.
Evidence snapshot
Evidence snapshot
Separate dimensions, not one overall score◎
Human evidenceEarly
1/5 evidence depth
No modern controlled human Pinealon treatment trial was identified.
✓
Clinical efficacyEarly
1/5 evidence depth
Memory, sleep, neuroprotection and anti-ageing efficacy are not established in people.
◇
Safety evidenceEarly
1/5 evidence depth
Human pharmacokinetics, route-specific exposure, interactions and long-term safety are not adequately characterised.
⌁
Preclinical evidenceDeveloping
3/5 evidence depth
Several cell and rodent studies support oxidative-stress, cognition and gene-regulation hypotheses.
HOW TO READ THESE SCORESDeveloping preclinical evidence · early human evidence
These are editorial evidence-depth ratings on a 1–5 scale, not a statistical result or a single scientific formula. They summarise how much relevant evidence is present in each separate category and how mature that evidence is.
Human evidenceHow much direct research in people is available and how developed it is.
Clinical efficacyWhether human studies demonstrate meaningful outcomes for the claims being discussed.
Safety evidenceHow much human safety, tolerability and longer-term follow-up information is available.
Preclinical evidenceThe depth of laboratory and animal research supporting biological plausibility.
EVIDENCE LANDSCAPEPinealonMechanism → measured response → clinical outcome
No modern controlled treatment trial identified
Cell and rodent studies across several models
Exposure, route, outcomes and long-term safety
Keep route, study setting and outcome together
A measured biological response can be valuable evidence without establishing a self-administered protocol or a durable treatment benefit.
From promising signals to human evidencePreclinical research can reveal promising biological signals. Human studies show how far those signals have translated into real-world outcomes.
What people are exploring
COMMUNITY · USE CASES & EXPERIENCE
What people want to change with Pinealon
Pinealon is explored for memory, mental clarity, sleep and healthy brain ageing. Those goals are understandable, but the direct evidence consists mainly of cell and rodent studies rather than human treatment outcomes.
Explore the everyday goalsConceptual scientific illustration
THE PRACTICAL ATTRACTION
The goals behind the interest
What the desired change means in daily life, and what makes an experience useful to understand.
Memory that feels more dependable
Interest centres on remembering names, retaining information and feeling less forgetful. The appeal comes from neural-cell research, with much less direct evidence for a noticeable treatment effect in people.
- What makes a report informative
- Specific memory tasks and everyday errors.
- What can muddy the picture
- Practice effects, stress and sleep can improve memory independently.
Clearer thinking during demanding work
People hope for more fluent thinking and less mental fatigue. A useful account identifies a practical task that became easier rather than only describing a brain-health feeling.
- What makes a report informative
- Concentration, task completion and mental stamina.
- What can muddy the picture
- Caffeine, other nootropics and workload changes complicate attribution.
Brain resilience with age
Healthy-ageing interest focuses on preserving cognitive capability. Experimental protection from cellular stress helps explain the hypothesis but cannot establish prevention of cognitive decline.
- What makes a report informative
- The distinction between cell research and measured human cognition.
- What can muddy the picture
- A bioregulator label is not evidence of a human anti-ageing benefit.
PUT THE EXPERIENCE IN CONTEXT
How the goals compare with the research
Open an area to distinguish human findings from laboratory explanations.
Memory and learning
This is the most common practical goal, with people looking for better recall or easier learning over a brief course.
Human findings & limits
No controlled human Pinealon trial establishes memory benefit.
Laboratory & animal context
Rodent stress, developmental and metabolic models report selected behavioural improvements.
What this means: A genuine animal-research theme that still lacks the human translation people care about.
Mental clarity and focus
Users describe subtle rather than stimulant-like changes and often combine use with other nootropics.
Human findings & limits
No validated healthy-user cognitive outcome or dose-response exists.
Laboratory & animal context
Cell-stress and neuronal gene-expression work provide indirect rationale.
What this means: Anecdotal experience cannot currently be separated from expectation or co-interventions.
Sleep and brain recovery
Some users place Pinealon in evening or recovery routines, although timing varies widely.
Human findings & limits
No polysomnography, insomnia or sleep-timing trial was identified.
Laboratory & animal context
Neural-stress research does not establish a sleep mechanism.
What this means: A popular extension beyond the published Pinealon evidence.
Short bioregulator courses
Ten-to-twenty-day cycles are repeated more consistently than any specific route or formulation.
Human findings & limits
No modern pharmacokinetic or dose-finding study validates the course.
Laboratory & animal context
Animal amounts cannot be converted directly to retail oral, nasal or injectable products.
What this means: A recognizable tradition-based pattern, not a clinically validated protocol.
Research sources and further reading
Dose & duration
DOSE & DURATION
Research protocols · community patterns · calculator toolsSee the numbers in their proper context
See the amount, how often it was used and how long each study ran. Published human research and community descriptions each carry their own source label, so you can see where the numbers came from.
Source matters. The figures below show authorised, human-research or community-described protocols in their original context — not a personalised recommendation.
ONE ANECDOTAL COMMUNITY EXAMPLE
ANECDOTAL · UNVALIDATEDA short-course tradition without a human dose-finding study
This example reflects recurring community descriptions. Pinealon has no controlled human pharmacokinetic or efficacy programme from which to derive the amount, route or repeat interval.
1Days 1–3
10 mg · once dailyAnecdotal starting amount
2Days 4–10
10 mg / dayNo evidence-led reason to escalate
3Days 11–20
Continue or stopCourse length varies in descriptions
4After course
Long pause & reviewNo validated repeat schedule
What people commonly discuss10 mg daily for 10–20 days is a frequently repeated anecdotal course; oral, nasal and injected descriptions are not equivalent.
What remains unvalidatedHuman exposure, dose-response, cognitive benefit, long-term safety and any one-to-three-month break remain unvalidated.
ROUTE & DELIVERYRoute changes exposure—and none is established
A milligram amount taken orally cannot be treated as equivalent to nasal or injected delivery. Product purity and concentration add separate uncertainty.
PROFESSIONAL SOURCE CONTEXT
No human dosing study availableThe source shows what has actually been studied. It does not validate the community example above or turn it into guidance.
No validated human Pinealon dose, route, titration schedule or maintenance course has been established.
No structured human dosing protocol has been added for this compound. That should not be interpreted as evidence for a community dosing schedule.
COMMUNITY DISCUSSION
Anecdotal / unvalidated · no controlled human dose-finding trialWhat people commonly discuss
STARTING APPROACHES
Community and longevity-clinic summaries commonly describe 10 mg daily; some divide the amount across one or two uses.
DURATION / CYCLES
Short 10–20-day courses are frequently repeated in anecdotal protocols rather than continuous use.
MAINTENANCE DISCUSSION
A one-to-three-month pause is sometimes described, but no evidence-based break or repeat-course interval exists.
Community patterns are anecdotal and unvalidated unless a linked human study independently supports the same approach.
CALCULATOR TOOLS
Work with the numbers
Convert amounts, concentration, liquid volume and vial requirements. These tools do the arithmetic; they do not select a dose.
NEED HELP READING THE NUMBERS?Source labels, routes and dose termsOpen guide +
HOW WE LABEL NUMBERSKnow where a dose came from before you compare it.
Authorised labelHuman trialCommunity-describedBEFORE THE NUMBERS: CHECK THE PRODUCT
Understand peptide testing →A dose only means something if the vial contains what the label says.
Purity, identity, quantity, sterility and endotoxin testing answer different questions. Learn how to read a COA and why a high purity percentage is not the same as confirming the amount in the vial.
READ THIS PAGE IN THREE STEPS
Understand the study before the number
A dose only makes sense alongside the population, route, frequency and duration. Start with where the number came from, then look at how it was delivered and how long the study actually ran.
1Source
Was it an authorised label, a human trial or a community-described pattern?
2Route & frequency
How was it given, and how often? The same number by a different route may not mean the same exposure.
3Duration
Was this one dose, a short trial or long-term treatment? A study window is not automatically a recommended cycle.
ROUTES EXPLAINED
Plain-English guideWhat do the injection types mean?
Route means how a compound was delivered. It affects absorption and can completely change how a study should be interpreted.
SubQ / SCSubcutaneous
An injection into the fatty layer just under the skin.
Common in peptide and metabolic-drug studies. It usually aims for systemic absorption rather than treating only the spot injected.IMIntramuscular
An injection into muscle tissue.
Muscle can absorb a medicine differently from fat. An IM amount should not be assumed to be equivalent to a SubQ amount.IVIntravenous
Delivered directly into a vein.
This gives immediate bloodstream exposure and is commonly used in supervised research or clinical settings. It is not interchangeable with a home injection route.INIntranasal
Delivered through the nose rather than by injection.
The amount delivered depends on formulation and device. A spray count alone does not tell you the dose unless concentration and spray volume are known.Other routes you may see:Oral = swallowed.Topical = applied to skin or another surface.Implant = a formulation placed under the skin by a trained professional.
CALENDAR SETUP
Twenty-day editorial example
Community example · not clinically validatedThe amounts and increases come from an editorial description. Preclinical findings do not establish a routine human Pinealon regimen.
Form and route: Injection under the skin, as described in the example
| Calendar stage | Amount each time |
|---|---|
| Days 1–5 | 1 mg |
| Days 6–14 | 1.5 mg |
| Days 15–20 | 2 mg |
Frequency: Every day · 1 entry per scheduled day.
The three stages cover exactly twenty days. No break or repeat course is generated.
PLAIN-ENGLISH GLOSSARYWhat do the dose terms mean?Open glossary +
mgmilligram
One thousand micrograms (mcg).
mcg / μgmicrogram
One thousandth of a milligram.
mcg/kgweight-based dose
The amount is calculated for each kilogram of body weight.
IUinternational unit
A measure of biological activity used for some medicines; it cannot be converted to mg without compound-specific information.
Routehow it was given
For example SubQ, IM, IV, intranasal, oral or topical.
Frequencyhow often
For example once daily, twice weekly or every seven days.
Titrationplanned step-up or step-down
A protocol changes the amount over time rather than using one fixed amount throughout.
Half-lifehow quickly levels fall
The time taken for the amount of a compound in the body to reduce by roughly half. It can influence study timing but does not by itself define a schedule.
Cyclea defined period of use
Usually means an on-period followed by a stop or review. Many community 'cycles' have not been clinically validated.
Maintenancea continuing phase
A longer-term amount or interval used after an initial phase when a study or authorised treatment actually defines one.
Reconstitutionturning powder into solution
Adding a specified liquid to a freeze-dried vial so a concentration can be calculated.
U-100 unitssyringe volume markings
100 units equals 1 mL on a U-100 insulin syringe. The markings show volume, not peptide mass.
Often combined with
OFTEN COMBINED WITH
Community rationale · component roles · evidence boundaryWhy people explore pairings with Pinealon
See the thinking behind community-named stacks, the different role each component is proposed to play, and how much of that idea has actually been tested as a combination.
Potential first, evidence in context. Pairings are usually explored because their research stories appear complementary. That makes them interesting to study, but does not yet prove extra benefit or safety.
CURRENT COMPOUNDPinealon
→
OFTEN EXPLORED WITHPinealon + Epitalon
Pinealon + Epitalon
→
OFTEN EXPLORED WITHPinealon + Semax
Pinealon + Semax
→
OFTEN EXPLORED WITHPinealon + cognitive-health plan
Pinealon + Sleep, hearing, mood and medication assessment
Combination-specific human research is the strongest evidence for what a pairing adds. Evidence for either ingredient alone should not be silently transferred to the combination.
PPINEALON IS USUALLY DISCUSSED AROUNDEDR, oxidative stress and preclinical cognition hypotheses
＋Cell and rodent work motivates interest, but no modern human trial establishes a cognitive or healthy-ageing effect.
PTHE PAIRED APPROACH MAY ADDCircadian bioregulators or a more acute nootropic narrative
Epitalon and Semax are discussed for different reasons; combining narratives does not create a tested benefit.
＋
OFTEN EXPLORED WITH
Explore →＋Pinealon + Epitalon
Pinealon + EpitalonWHY IT IS EXPLOREDThe pairing combines neural-ageing and pineal/circadian bioregulator narratives.
No controlled human study establishes cognitive, sleep or longevity synergy.OFTEN EXPLORED WITH
Explore →＋Pinealon + Semax
Pinealon + SemaxWHY IT IS EXPLOREDCommunities combine a slow 'bioregulator' story with a more acute neurotrophic/nootropic one.
No human combination evidence; overlapping CNS effects and product uncertainty remain.OFTEN EXPLORED WITH
Explore →Pinealon + cognitive-health plan
Pinealon + Sleep, hearing, mood and medication assessmentWHY IT IS EXPLOREDTreatable contributors to cognitive symptoms can otherwise be mistaken for a peptide response.
The assessment and lifestyle components have independent value; Pinealon has not been shown to add benefit.01Define the problem first
Memory change, poor sleep, low mood and medication effects require different assessment.
02Do not merge preclinical signals
Separate animal studies cannot demonstrate synergy in people.
03Use one change at a time
Multiple neuroactive products make both benefit and adverse effects difficult to interpret.
Safety context
SAFETY & UNCERTAINTY
The main safety problem is how little human exposure information exists
01ENCOURAGING CONTEXTThe EDR sequence is precise and experimentally testable
Peer-reviewed cell and rodent studies give the neural-stress and cognition hypotheses a real research foundation.
02THE IMPORTANT BOUNDARYNo controlled human benefit has been demonstrated
Animal learning or cell-viability changes cannot establish better memory, sleep or healthy ageing in people.
03WHAT REMAINS UNKNOWNAlmost the entire human safety profile
Pharmacokinetics, bioavailability, dose-response, interactions, long-term neurological effects and repeat-course safety are not adequately characterised.
What the current evidence saysA tripeptide can sound simple, but product identity, purity, route, bioavailability and neurological interactions remain separate questions. New or worsening cognitive symptoms, focal neurological signs, seizures, severe headache or marked mood change require clinical assessment rather than continued experimentation.
01 · OBSERVEDPublished safety findings
The summary above reflects the human or preclinical evidence currently represented on this profile.
02 · UNCERTAINGaps still matter
Limited follow-up, small studies or absent controlled trials can leave uncommon and longer-term risks unresolved.
03 · CONTEXTProduct and regulatory status
Route, product identity, quality and regulatory status can materially change the safety context; see the linked status sources below.
Sleep disorders, hearing problems, depression, thyroid disease, medication effects and neurological illness can all affect memory.
Oral, nasal and injected products are not equivalent, and identity, concentration and contamination remain product-level risks.
Seizure, severe headache, focal weakness, marked confusion or major mood change should prompt urgent clinical review.
Sources & current status
READ FURTHER
Sources & current status
Follow the professional sources used across this profile, then see how the compound is currently described in regulatory and research terms.
KEY RESEARCH RECORD
6 sourcesSources used on this profile
Original cell researchPinealon increases cell viability under oxidative stressPublisher article ↗Original animal researchPinealon in rat offspring exposed to prenatal hyperhomocysteinaemiaFree full paper ↗Bibliographic recordPinealon in rat offspring exposed to prenatal hyperhomocysteinaemiaPubMed ↗Bibliographic recordPinealon and Cortexin in aged rats exposed to hypoxia or hypothermiaPubMed ↗Professional sourceUnited KingdomMHRA products database ↗Professional sourceUnited StatesFDA Drugs@FDA database ↗
CURRENT STATUS
How to interpret its position today
No UK-authorised medicine is represented on this profile
Pinealon is presented as a research compound. The MHRA products database should be checked for any future change in authorised status.
MHRA products database ↗No FDA-approved therapeutic product identified
Regulatory evaluation of a substance for compounding is separate from approval of a drug for safety and efficacy.
FDA Drugs@FDA database ↗Profile reviewed against its linked source record on 20 September 2026. See how evidence is assessed.